NeuroPace Inc (NASDAQ: NPCE) disclosed that its Chief Medical Officer, Martha Morrell, sold 25,000 shares of common stock on December 15, 2025. The shares were sold at an average price of $15.97 for an aggregate proceeds amounting to $399,250. Reported execution prices for the transaction ranged between $15.83 and $16.26. The filing notes that the December sale was carried out under a pre-arranged Rule 10b5-1 trading plan.
Since that sale, NeuroPace shares have retreated from the December trading range. The stock is currently quoted at $13.95, below the levels at which Morrell sold, though the shares have still delivered a 43% gain over the past six months.
In a separate compensation-related transaction, NeuroPace withheld 1,340 shares from Morrell on March 3, 2026, to satisfy tax withholding tied to the vesting of restricted stock units. Those withheld shares were valued at $13.83 apiece, producing a total withholding value of $18,532.
Following the December sale and the March withholding, Morrell is recorded as the direct owner of 48,624 NeuroPace shares.
On the operational and financial front, NeuroPace - a medical device company with a reported valuation of $470 million - posted 25% revenue growth over the last twelve months. The company also reported a strong liquidity position, with a current ratio of 5.28.
The company reported fourth-quarter 2025 results that exceeded analyst expectations. NeuroPace posted an earnings per share figure of -0.08, ahead of the consensus estimate of -0.18, representing a 55.56% surprise. Revenue for the quarter reached $26.6 million, compared with the expected $24.39 million.
Despite the outperformance on both EPS and revenue versus analyst projections, the stock experienced downward pressure following the earnings release. The filing and subsequent market moves point to a company that is delivering higher-than-expected near-term financial results while trading below the prices at which an insider liquidated a substantial block of shares late last year.
Market valuation perspectives included in available analysis indicate that NeuroPace may appear overvalued at current prices based on Fair Value calculations from InvestingPro, with a recommendation for investors to consult the full Pro Research Report for more detailed financial and valuation context.
The transactions reported here - an insider sale under a Rule 10b5-1 plan and routine tax withholding on vested RSUs - are common elements of executive compensation and portfolio management. They add to the public record as investors weigh the companys recent operating results, reported liquidity metrics, and prevailing share price.